Board of Directors and Advisors
Co-Founder and Advisor
Justin Lynch is a Partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team in early 2007 prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science. Justin has a particular interest in the medical device sector and leads the firms investments in Neuravi and Vivasure Medical where he also serves as a board member.
Maurice Roche is a General Partner with Delta Partners having joined Delta in 1995. He has over 25 years experience of advising and investing in early stage technologies companies, 20 of those as a Venture Capitalist.
Maurice serves as a non-executive director of a number of companies including Cleverbug, Digit Games Studios, Homestays, Hullomail, Tango Telecom, textHELP, WhatClinic.com and Zapa Technology. He was also previously a non-executive director of Xiam Technology Limited sold to Qualcomm (NASDAQ: QCOM), Pxit sold to Agilent (NYSE: A), O’Leary’s (sold to Gehe, now Celesio Group) and Polarlake sold to Bloomberg.
A graduate of University of Limerick in Business Studies, he holds a postgraduate degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.
He is a former Chairman of the Irish Venture Capital Association (July 2011 to June 2012). He was a member of the Research Prioritisation Project Steering Group which was chaired by Jim O’Hara (October 2010 to September 2011). This group was asked to make recommendations to Government on areas of focus for the next phase of Ireland’s science, technology and innovation strategy. The report was published by Forfas in March 2012.
Mahmood Razavi, MD
Co-Founder and Advisor
A world renowned thought leader in the endovascular field, Dr. Razavi is an Interventional Radiologist at St. Joseph’s Vascular Institute in Orange, California, USA. He was formerly Associate Professor at the Stanford University Medical Center and the Director of the fellowship program at the Stanford Vascular Center. He has acted as a Scientific Advisory Board member or Consultant to Abbott Laboratories, Johnson and Johnson, Edwards Life Science, Covidien, C.R. Bard and a number of other small and large companies. Also an experienced entrepreneur, he co-founded Trivascular Inc, a company that developed aortic vascular endografts and which was sold to Boston Scientific in 2003. He has authored or co-authored more than 250 scientific publications. He received his medical degree from the University of Southern California and completed his Radiology residency at UCLA.
CEO and Co-Founder
With over two decades of experience in the medical device industry, Eamon previously led international teams as both Global Director of R&D and Director of New Ventures at Abbott Vascular. In these roles, he led the global R&D team to multiple product launches and was responsible for worldwide business development activities within the neurovascular, stenting, embolic protection, endo-AAA, and venous fields. He was a member of the founding team of MedNova Ltd., a company that pioneered embolic protection for carotid stenting, and helped lead the company to a $100M acquisition by Abbott Vascular. Eamon is an inventor on over 150 US patents, granted or pending.
Chairman and Co-Founder
John has over 30 years experience in the medical device industry and is one of the most experienced medical device leaders in Ireland. He ran Medtronic’s cardiovascular business in Galway for 15 years and was the founder and CEO of MedNova Ltd. MedNova pioneered embolic protection for endovascular treatment of carotid artery disease and gained worldwide approval for its products. John serves as Chairman of Vistamed Limited and Cambus Teoranta, and he served as Non-Executive Director of IDA Ireland from 1995 to 2000. He was a founder of Croi, the West of Ireland Cardiac Foundation, a voluntary organization to support the fight against heart disease and stroke.
Bob brings to Neuravi over twenty-five years of public company and private company experience leading and building medical device and biotechnology companies, both in management and board roles. He has served as President and CEO of Vascular Dynamics, a blood pressure modulation company, since November 2011, where he led a $14M financing round. He has extensive experience in the field of endovascular stroke intervention, having served as President, COO of Micrus Endovascular (MEND). Micrus was acquired by Johnson & Johnson in 2010. Prior to Micrus, Mr. Stern served as President and Chief Executive Officer of Context Connect, a wireless technology company; as Executive Vice President and Chief Financial Officer of Qixel Capital Corporation, an internet holding company; and as Vice President and Chief Financial Officer of InnerDyne Inc. (IDYN), a surgical access and biotechnology company acquired by US Surgical. Bob served on the boards of Reverse Medical acquired by Covidien, and Flexible Stenting Solutions acquired by Johnson and Johnson, and Nexeon Medsystems.
Mr. Stern received his B.S. in Business Administration from the University of New Hampshire, Whittemore School of Business and Economics, and his MBA from the University of New Mexico, Anderson School of Management.
Anne Portwich, PhD, joined LSP in 2001. She became a Partner of the firm in 2011. Anne’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Anne was a Scientist and Project Leader at OctoPlus, a Dutch company offering advanced research services to pharmaceutical and biotechnology companies. Anne brings hands-on research and industry experience to the LSP team, as well as an analytical mind with great attention to detail. Among others, she currently serves as a Director of Mint Solutions, a Dutch company that is providing a medication safety solution for hospitals and healthcare institutions. Anne has been directly involved in the establishment of a number of start-ups as well as in initiatives that support the growth of such companies. Anne is a jury member of New Venture, a business plan competition for start-up companies in the Netherlands as well as a member of the evaluation panel for Tekes’ Young Innovative Growth Companies (YIC) funding program in Finland. Anne obtained an MSc in biochemistry from the University of Hanover and received her PhD from the Max Planck-Institute of Marine Microbiology in Bremen.
René Kuijten MD PhD MBA, joined LSP in 2001. He became a Partner and co-owner of the firm in that same year. His prime focus and responsibility within LSP is to invest in unlisted securities and the general management of the firm. Prior to joining LSP, René was a senior consultant at McKinsey & Company in Amsterdam, Brussels and Zurich, where he was responsible for McKinsey’s European Healthcare Practice. René has been appointed a Director of a large number of companies, all of which he has helped to grow by leveraging his in-depth knowledge of the healthcare industry, his analytical skills and his global networks. René is currently also a Director of the Dutch Venture Capital Association (NVP), in which role he initiated the Dutch Venture Initiative (DVI), a EUR 150 million government-backed fund-of-fund that invests in the top-tier Dutch Venture firms. Furthermore he is, a.o., a member of the national Topsector Life Sciences & Health; Chairman of the Emma Children’s Hospital charity; and Advisory Board member of the Vereniging Rembrandt. As an MD PhD, René has a strong background in medicine and science. He went to the University of Utrecht, Harvard Medical School, the Mayo Clinics and the University of Pennsylvania where he published a.o. in The New England Journal of Medicine. In addition, René obtained an MBA from INSEAD in Fontainebleau, France.